Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab intensification in ctDNA MRD-positive PD-L1-positive locally advanced head and neck squamous cell carcinoma after chemoradiation
2025-523575-36-00Phase 2Authorised
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ezabenlimab in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Event-free survival rate at 2 years. Planned start Apr 2026; status: authorised.
02
Drugs
ezabenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-523575-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523575-36-00.